Fundies.
English

Segment disclosures

Company overview

Arbutus Biopharma Corporation

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

1 dimension combinations 16 retained observations 11 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Reportable Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=abus:ReportableSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-301014000 USD20260812Open filing evidence
2026-01-01 – 2026-06-30180140000 USD20260812Open filing evidence
2026-01-01 – 2026-03-31179126000 USD20260513Open filing evidence
2025-01-01 – 2025-12-3114083000 USD20260323Open filing evidence
2025-07-01 – 2025-09-30529000 USD20251113Open filing evidence
2025-01-01 – 2025-09-3013032000 USD20251113Open filing evidence
2025-04-01 – 2025-06-3010739000 USD20260812Open filing evidence
2025-01-01 – 2025-06-3012503000 USD20260812Open filing evidence
2025-01-01 – 2025-03-311764000 USD20260513Open filing evidence
2024-01-01 – 2024-12-316171000 USD20260323Open filing evidence
2024-07-01 – 2024-09-301339000 USD20251113Open filing evidence
2024-01-01 – 2024-09-304597000 USD20251113Open filing evidence
2024-04-01 – 2024-06-301726000 USD20250806Open filing evidence
2024-01-01 – 2024-06-303258000 USD20250806Open filing evidence
2024-01-01 – 2024-03-311532000 USD20250514Open filing evidence
2023-01-01 – 2023-12-3118141000 USD20250327Open filing evidence